Assessment of a prognostic MRI biomarker in early de novo Parkinson's disease

Publication date: Available online 19 August 2019Source: NeuroImage: ClinicalAuthor(s): Yashar Zeighami, Seyed-Mohammad Fereshtehnejad, Mahsa Dadar, D. Louis Collins, Ronald B. Postuma, Alain DagherAbstractBackgroundCommonly used neuroimaging biomarkers in Parkinson's disease (PD) are useful for diagnosis but poor at predicting outcomes. We explored whether an atrophy pattern from whole-brain structural MRI, measured in the drug-naïve early stage, could predict PD prognosis.Methods362 de novo PD patients with T1-weighted MRI (n = 222 for the main analysis, 140 for the validation analysis) were recruited from the Parkinson's Progression Markers Initiative (PPMI). We investigated a previously identified PD-specific network atrophy pattern as a potential biomarker of disease severity and prognosis. Progression trajectories of motor function (MDS-UPDRS-part III), cognition (Montreal Cognitive Assessment (MoCA)), and a global composite outcome measure were compared between atrophy tertiles using mixed effect models. The prognostic value of the MRI atrophy measure was compared with 123I ioflupane single photon emission computed tomography, the postural-instability-gait-disturbance score, and cerebrospinal fluid markers.FindingsAfter 4.5 years follow-up, PD-specific atrophy network score at baseline significantly predicted change in UPDRS-part III (r = −0.197, p = .003), MoCA (r = 0.253, p = .0002) and global composite outcome (r = −0.249, p = .000...
Source: NeuroImage: Clinical - Category: Radiology Source Type: research